The DOI matches its Crossref record; 265 of the 265 references it cites were found in a registry or an index.
A Practical Review of Proteasome Pharmacology
Open accessAbstract
The ubiquitin proteasome system (UPS) degrades individual proteins in a highly regulated fashion and is responsible for the degradation of misfolded, damaged, or unneeded cellular proteins. During the past 20 years, investigators have established a critical role for the UPS in essentially every cellular process, including cell cycle progression, transcriptional regulation, genome integrity, apoptosis, immune responses, and neuronal plasticity. At the center of the UPS is the proteasome, a large and complex molecular machine containing a multicatalytic protease complex. When the efficiency of this proteostasis system is perturbed, misfolded and damaged protein aggregates can accumulate to toxic levels and cause neuronal dysfunction, which may underlie many neurodegenerative diseases. In addition, many cancers rely on robust proteasome activity for degrading tumor suppressors and cell cycle checkpoint inhibitors necessary for rapid cell division. Thus, proteasome inhibitors have proven clinically useful to treat some types of cancer, especially multiple myeloma. Numerous cellular processes rely on finely tuned proteasome function, making it a crucial target for future therapeutic intervention in many diseases, including neurodegenerative diseases, cystic fibrosis, atherosclerosis, autoimmune diseases, diabetes, and cancer. In this review, we discuss the structure and function of the proteasome, the mechanisms of action of different proteasome inhibitors, various techniques to evaluate proteasome function in vitro and in vivo, proteasome inhibitors in preclinical and clinical development, and the feasibility for pharmacological activation of the proteasome to potentially treat neurodegenerative disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 201–265 of 265
Open-gate mutants of the mammalian proteasome show enhanced ubiquitin-conjugate degradation
Choi, W. H., de Poot, S. A. H., Lee, J. H., Kim, J. H., Han, D. H., Kim, Y. K., Finley, D. J., & Lee, M. J. (2016) · Nature Communications · doi:10.1038/ncomms10963 · Cited by 100
Li, X., Wang, C.-E., Huang, S., Xu, X., Li, X., Li, H., & Li, S. (2010) · Human Molecular Genetics · doi:10.1093/hmg/ddq127 · Cited by 99
Noxa/Bcl-2 Protein Interactions Contribute to Bortezomib Resistance in Human Lymphoid Cells
Smith, A. J., Dai, H., Correia, C., Takahashi, R., Lee, S. H., Schmitz, I., & Kaufmann, S. H. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.189092 · Cited by 98
Enzymic Content of the Mitochondria Fraction
Duve, C. D., Gianetto, R., Appelmans, F., & Wattiaux, R. (1953) · Nature · doi:10.1038/1721143a0 · Cited by 93
Kim, H. T., & Goldberg, A. L. (2017) · Journal of Biological Chemistry · doi:10.1074/jbc.m116.763128 · Cited by 92
Lü, S., Chen, Z., Yang, J., Chen, L., Gong, S., Zhou, H., Guo, L., & Wang, J. (2008) · Experimental Hematology · doi:10.1016/j.exphem.2008.04.013 · Cited by 91
Hoyt, M. A., Zhang, M., & Coffino, P. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m211802200 · Cited by 89
Is the ubiquitin-proteasome system impaired in Huntington’s disease?
Ortega, Z., Díaz-Hernández, M., & Lucas, J. J. (2007) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-007-7222-8 · Cited by 86
Kuhn, D. J., Orlowski, R. Z., & Bjorklund, C. C. (2011) · Current Cancer Drug Targets · doi:10.2174/156800911794519725 · Cited by 86
Application and Analysis of the GFPu Family of Ubiquitin‐Proteasome System Reporters
Bence, N., Bennett, E. J., & Kopito, R. R. (2005) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/s0076-6879(05)99033-2 · Cited by 84
Roccaro, A., Sacco, A., Aujay, M., Ngo, H., Azab, A., Azab, F., Quang, P., Maiso, P., Runnels, J., Anderson, K., et al. (2010) · Blood · doi:10.1182/blood-2009-09-243402 · Cited by 84
Ubiquitin-dependent proteolysis: its role in human diseases and the design of therapeutic strategies
Sakamoto, K. M. (2002) · Molecular Genetics and Metabolism · doi:10.1016/s1096-7192(02)00146-4 · Cited by 82
A high-throughput, multiplexed assay for superfamily-wide profiling of enzyme activity
Bachovchin, D. A., Koblan, L. W., Wu, W., Liu, Y., Li, Y., Zhao, P., Woźnica, I., Shu, Y., Lai, J. H.-S., Poplawski, S. E., et al. (2014) · Nature Chemical Biology · doi:10.1038/nchembio.1578 · Cited by 78
Dietrich, C., Bartsch, T., Schanz, F., Oesch, F., & Wieser, R. J. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.20.10815 · Cited by 75
The ubiquitin–proteasome system and neurodegenerative disorders
Layfield, R., Lowe, J. S., & Bedford, L. (2005) · Essays in Biochemistry · doi:10.1042/eb0410157 · Cited by 71
Safety of proteasome inhibitors for treatment of multiple myeloma
Schlafer, D., Shah, K. S., Panjic, E. H., & Lonial, S. (2016) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2017.1259310 · Cited by 71
A Novel Role for PA28γ-Proteasome in Nuclear Speckle Organization and SR Protein Trafficking
Baldin, V., Militello, M., Thomas, Y., Doucet, C. M., Fic, W., Boireau, S., Jariel‐Encontre, I., Piechaczyk, M., Bertrand, É., Tazi, J., et al. (2008) · Molecular Biology of the Cell · doi:10.1091/mbc.e07-07-0637 · Cited by 68
Chou, T., & Deshaies, R. J. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.215319 · Cited by 64
Knowles, S. E., Gunn, J. M., Hanson, R. W., & Ballard, F. J. (1975) · Biochemical Journal · doi:10.1042/bj1460595 · Cited by 64
Santos, R. D. L. A., Bai, L., Singh, P. K., Murakami, N., Fan, H., Zhan, W., Zhu, Y., Jiang, X., Zhang, K., Assker, J. P., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-01760-5 · Cited by 62
Nature of Pharmacophore Influences Active Site Specificity of Proteasome Inhibitors
Screen, M., Britton, M., Downey-Kopyscinski, S. L., Verdoes, M., Voges, M. J. E. E. E., Blom, A. E. M., Geurink, P. P., Risseeuw, M., Florea, B. I., van der Linden, W. A., et al. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.160606 · Cited by 61
Cryo-EM reveals the conformation of a substrate analogue in the human 20S proteasome core
da Fonseca, P. C. A., & Morris, E. P. (2015) · Nature Communications · doi:10.1038/ncomms8573 · Cited by 58
Formation of Proteasome−PA700 Complexes Directly Correlates with Activation of Peptidase Activity
Adams, G. M., Crotchett, B., Slaughter, C. A., Demartino, G., & Gogol, E. P. (1998) · Biochemistry · doi:10.1021/bi981482i · Cited by 56
Development of Peptide-Based Reversing Agents for P-Glycoprotein-Mediated Resistance to Carfilzomib
Ao, L., Wu, Y., Kim, D., Jang, E. R., Kim, K., Lee, D.-M., Kim, K. B., & Lee, W. (2012) · Molecular Pharmaceutics · doi:10.1021/mp300044b · Cited by 55
Novel Proteasome Inhibitors and Histone Deacetylase Inhibitors: Progress in Myeloma Therapeutics
Chhabra, S. (2017) · Pharmaceuticals · doi:10.3390/ph10020040 · Cited by 55
Mateos, M., Masszi, T., Grząśko, N., Hansson, M., Sandhu, I., Pour, L., Viterbo, L., Jackson, S. R., Stoppa, A., Gimsing, P., et al. (2017) · Haematologica · doi:10.3324/haematol.2017.170118 · Cited by 55
Otero, M. G., Alloatti, M., Cromberg, L. E., Almenar‐Queralt, A., Encalada, S. E., Devoto, V. M. P., Bruno, L., Goldstein, L. S. B., & Falzone, T. L. (2014) · Journal of Cell Science · doi:10.1242/jcs.140780 · Cited by 54
Levin, N., Spencer, A. G., Harrison, S. J., Chauhan, D., Burrows, F. J., Anderson, K. C., Reich, S. D., Richardson, P. G. G., & Trikha, M. (2016) · British Journal of Haematology · doi:10.1111/bjh.14113 · Cited by 54
Detailed analysis of cell cycle kinetics upon proteasome inhibition
Machiels, B. M., Henfling, M. E. R., Gerards, W. L. H., Broers, J. L. V., BLOEMENDAL, H., Ramaekers, F. C. S., & Schütte, B. (1997) · Cytometry · Cited by 53
Heat‐Inducible Degron and the Making of Conditional Mutants
Dohmen, R. J., & Varshavsky, A. J. (2005) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/s0076-6879(05)99052-6 · Cited by 51
Kraus, M., Bader, J. E., Geurink, P. P., Weyburne, E. S., Mirabella, A., Silzle, T., Shabaneh, T. B., van der Linden, W. A., de Bruin, G., Haile, S. R., et al. (2015) · Haematologica · doi:10.3324/haematol.2014.109421 · Cited by 51
A Rapid and Versatile Method for Generating Proteins with Defined Ubiquitin Chains
Martinez‐Fonts, K., & Matouschek, A. T. (2016) · Biochemistry · doi:10.1021/acs.biochem.5b01310 · Cited by 48
Cecarini, V., Bonfili, L., Amici, M., Angeletti, M., Keller, J. N., & Eleuteri, A. M. (2008) · Brain Research · doi:10.1016/j.brainres.2008.03.003 · Cited by 46
Dependence of Proteasome Processing Rate on Substrate Unfolding
Henderson, A., Erales, J., Hoyt, M. A., & Coffino, P. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.212027 · Cited by 46
Hideshima, T., Chauhan, D., Ishitsuka, K., Yasui, H., Raje, N. S., Kumar, S. K., Podar, K., Mitsiades, C. S., Hideshima, H., Bonham, L., et al. (2005) · Oncogene · doi:10.1038/sj.onc.1208522 · Cited by 46
Carfilzomib: A new proteasome inhibitor for relapsed or refractory multiple myeloma
Steele, J. M. (2013) · Journal of Oncology Pharmacy Practice · doi:10.1177/1078155212470388 · Cited by 44
Activity‐based probes for the multicatalytic proteasome
Hewings, D. S., Flygare, J. A., Wertz, I. E., & Bogyo, M. S. (2017) · FEBS Journal · doi:10.1111/febs.14016 · Cited by 43
Sha, Z., Zhao, J., & Goldberg, A. L. (2018) · Methods in molecular biology · doi:10.1007/978-1-4939-8706-1_17 · Cited by 42
Affinity Purification of Mammalian 26S Proteasomes Using an Ubiquitin-Like Domain
Besche, H. C., & Goldberg, A. L. (2012) · Methods in Molecular Biology · doi:10.1007/978-1-61779-474-2_29 · Cited by 39
Johnson, H. W. B., Anderl, J. L., Bradley, E. K., Bui, J., Jones, J. A., Arastu‐Kapur, S., Kelly, L. M., Lowe, E., Moebius, D. C., Muchamuel, T., et al. (2017) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.6b00496 · Cited by 39
The proteasome controls the expression of a proliferation-associated nuclear antigen Ki-67
Wu, Y., Luo, H., Kanaan, N., & Wu, J. (2000) · Journal of Cellular Biochemistry · Cited by 38
The proteasome 11S regulator subunit REGα (PA28α) is a heptamer
Johnston, S. C., Whitby, F. G., Realini, C. A., Rechsteiner, M., & Hill, C. P. (1997) · Protein Science · doi:10.1002/pro.5560061123 · Cited by 38
Enzler, T., Sano, Y., Choo, M., Cottam, H. B., Karin, M., Tsao, H., & Park, J. M. (2011) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0143 · Cited by 38
Liu, H., Wan, C., Ding, Y., Han, R., He, Y., Xiao, J., & Hao, J. (2017) · The FASEB Journal · doi:10.1096/fj.201601147r · Cited by 37
Laubach, J. P., Mitsiades, C. S., Roccaro, A. M., Ghobrial, I. M., Anderson, K. C., & Richardson, P. G. G. (2009) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428190902866732 · Cited by 36
Doxorubicin induces atypical NF-κB activation through c-Abl kinase activity in breast cancer cells
Esparza‐López, J., Medina‐Franco, H., Escobar-Arriaga, E., León‐Rodríguez, E., Zentella‐Dehesa, A., & Ibarra-Sánchez, M. D. J. (2013) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-013-1476-3 · Cited by 35
Blickwedehl, J., Olejniczak, S. H., Cummings, R., Sarvaiya, N., Mantilla, A., Chanan-Khan, A. A., Pandita, T. K., Schmidt, M., Thompson, C. B., & Bangia, N. (2012) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-11-0493-t · Cited by 34
Monitoring of Ubiquitin‐Dependent Proteolysis with Green Fluorescent Protein Substrates
Menéndez-Benito, V., Heessen, S., & Dantuma, N. P. (2005) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/s0076-6879(05)99034-4 · Cited by 32
Witkowska, J., Giżyńska, M., Grudnik, P., Golik, P., Karpowicz, P., Giełdoń, A., Dubin, G., & Jankowska, E. (2017) · Scientific Reports · doi:10.1038/s41598-017-05997-4 · Cited by 31
Novel proteasome inhibitor ixazomib sensitizes neuroblastoma cells to doxorubicin treatment
Li, H., Chen, Z., Hu, T., Wang, L., Yu, Y., Zhao, Y., Sun, W., Guan, S., Pang, J. C., Woodfield, S. E., et al. (2016) · Scientific Reports · doi:10.1038/srep34397 · Cited by 27
Dasuri, K., Ebenezer, P. J., Zhang, L., Fernandez‐Kim, S. O., Uranga, R. M., Gavilán, E., Blasio, A. D., & Keller, J. N. (2010) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2010.07.014 · Cited by 26
Native Gel Approaches in Studying Proteasome Assembly and Chaperones
Roelofs, J., Suppahia, A., Waite, K. A., & Park, S. (2018) · Methods in molecular biology · doi:10.1007/978-1-4939-8706-1_16 · Cited by 26
Lickliter, J. D., Bomba, D., Anderl, J. L., Fan, A., Kirk, C. J., & Wang, J. (2018) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2018-eular.3344 · Cited by 25
Targeted treatments for multiple myeloma: specific role of carfilzomib
Vij, R., Sugumar, D., & Keller, J. (2015) · Pharmacogenomics and Personalized Medicine · doi:10.2147/pgpm.s39085 · Cited by 23
Bhattacharyya, S., Renn, J. P., Yu, H., Marko, J. F., & Matouschek, A. T. (2016) · Analytical Biochemistry · doi:10.1016/j.ab.2016.05.026 · Cited by 23
Fan, Q., & Liu, B. (2017) · OncoTargets and Therapy · doi:10.2147/ott.s139686 · Cited by 21
The Proteasomal ATPases Use a Slow but Highly Processive Strategy to Unfold Proteins
Snoberger, A. M., Anderson, R. T., & Smith, D. M. (2017) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2017.00018 · Cited by 20
Self-citationThe N-end rule of selective protein turnover: mechanistic aspects and functional implications
Varshavsky, A. J., Bachmair, A., & Finley, D. J. (1987) · Biochemical Society Transactions · doi:10.1042/bst0150815 · Cited by 19
Csizmadia, V., Hales, P., Tsu, C. A., Ma, J., Chen, J., Shah, P., Fleming, P. E., Senn, J. J., Kadambi, V. J., Dick, L. R., et al. (2016) · Toxicology Research · doi:10.1039/c6tx00220j · Cited by 19
High-resolution cryo-EM proteasome structures in drug development
Morris, E. P., & da Fonseca, P. C. A. (2017) · Acta Crystallographica Section D Structural Biology · doi:10.1107/s2059798317007021 · Cited by 13
Dechavanne, V., Vilbois, F., Glez, L., & Antonsson, B. E. (2012) · Protein Expression and Purification · doi:10.1016/j.pep.2012.10.009 · Cited by 12
Methods to Rapidly Prepare Mammalian 26S Proteasomes for Biochemical Analysis
Kuo, C.-L., Collins, G. A., & Goldberg, A. L. (2018) · Methods in molecular biology · doi:10.1007/978-1-4939-8706-1_18 · Cited by 11
Monitoring the Distribution and Dynamics of Proteasomes in Living Cells
Groothuis, T. A., & Reits, E. A. (2005) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/s0076-6879(05)99037-x · Cited by 9
Scalable In Vitro Proteasome Activity Assay
Gautam, A. K. S., Martinez‐Fonts, K., & Matouschek, A. T. (2018) · Methods in molecular biology · doi:10.1007/978-1-4939-8706-1_21 · Cited by 8
Ubiquitin-fusion as a strategy to modulate protein half-life: A3G antiviral activity revisited
Cadima-Couto, Í., Freitas‐Vieira, A., Nowarski, R., Britan‐Rosich, E., Kotler, M., & Gonçalves, J. (2009) · Virology · doi:10.1016/j.virol.2009.07.031 · Cited by 3
Cited by
Targeting the ubiquitin-proteasome pathway to overcome anti-cancer drug resistance
Narayanan, S., Cai, C.-Y., Assaraf, Y. G., Guo, H.-Q., Cui, Q., Wei, L., Huang, J.-J., Ashby, C. R., & Chen, Z.-S. (2020) · Drug Resistance Updates · doi:10.1016/j.drup.2019.100663 · Cited by 332
Fricker, L. D. (2020) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010919-023603 · Cited by 309
Proteolysis‐targeting chimeras in drug development: A safety perspective
Moreau, K., Coen, M., Zhang, A. X., Pachl, F., Castaldi, M. P., Dahl, G., Boyd, H., Scott, C., & Newham, P. (2020) · British Journal of Pharmacology · doi:10.1111/bph.15014 · Cited by 229
Small-Molecule Degraders beyond PROTACs—Challenges and Opportunities
Kastl, J. M., Davies, G., Godsman, E., & Holdgate, G. A. (2021) · SLAS Discovery · doi:10.1177/2472555221991104 · Cited by 43
Cao, C., Wang, K., Wang, Y., Liu, T.-B., Rivera, A., & Xue, C. (2022) · Nature Communications · doi:10.1038/s41467-022-34151-6 · Cited by 18
Metadata
- Authors
- Thibaudeau, T. A., & Smith, D. M.
- Venue
- Pharmacological Reviews
- Publisher
- Elsevier BV
- Published
- 2019-04
- Volume
- 71
- Issue
- 2
- Pages
- 170-197
- ISSN
- 0031-6997 (ISSN-L)
- OpenAlex
- W2921234630
- Cited by
- 344
- References
- 265
- FWCI
- 12.68
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.